Lycorine derivatives, pharmaceutical composition thereof and application of lycorine derivatives in preparation of antiviral drugs

By optimizing the structure of arylamine, arylamine derivatives with different acyl substitutions were developed, which solved the problem of limited effect of arylamine in anti-CoV, and achieved significant antiviral activity and low toxicity. Effect.

CN118894866AActive Publication Date: 2024-11-05INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202310491782.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-04
Publication Date
2024-11-05
Estimated Expiration
2043-05-04

AI Technical Summary

Technical Problem

Aralisin has drug properties such as strong hydrophilicity, poor metabolic stability and toxic side effects, and is difficult to develop as an effective antiviral drug, especially in terms of its effect in anti-coronavirus SARS-CoV-2.

Method used

By optimizing the structural optimization of 2-position hydroxyl group to carbonyl group of syrupine, a class of syrupine derivatives, including compounds with different acyl substitutions, such as LY155, LY208 and LY211, to form pharmaceutical compositions to improve antivirals to improve antiviral active.

Benefits of technology

These derivatives show significant anti-CoV activity, have good antiviral prospects, and show high inhibition rates and low toxicity in in vitro initial screening and assays, suggesting their potential in drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894866A_ABST
    Figure CN118894866A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicine, discloses lycorine derivatives, pharmaceutical compositions thereof and application of the lycorine derivatives in preparation of antiviral drugs, and particularly relates to the lycorine derivatives shown in the general formula (I), pharmaceutically acceptable salts of the lycorine derivatives, the pharmaceutical compositions of the lycorine derivatives and application of the lycorine derivatives. The lycorine derivative has obvious antiviral activity and can be used for treating viral diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to a class of lycorine derivatives and a preparation method thereof, a pharmaceutical composition containing the same, and the use of the lycorine derivatives in preparing antiviral drugs. Background Art

[0002] Lycorine (LY) was first isolated from Narcissus pseudonarcissus in 1877 and is widely distributed in Amaryllidaceae plants. Studies have shown that Lycorine (structural formula below) has a strong broad-spectrum antiviral effect, including coronavirus (SARS-CoV), dengue virus (DENV), West Nile virus (WNV), retrovirus (HIV-1), herpes simplex virus (HSV-1), polio virus (PV), enterovirus (EV71), influenza virus (H5N1), hepatitis C virus (HCV), yellow fever virus (YFV), Zika virus (ZIKV), etc.

[0003] Recent studies have reported that lycorine has in vitro anti-new coronavirus (SARS-CoV-2) activity, and its strength of action is comparable to that of remdesivir. Since lycorine itself has drug-like defects such as strong hydrophilicity, poor metabolic stability, and toxic side effects, the development of lycorine-based broad-spectrum antiviral drugs is a top priority. The inventor also previously disclosed a class of lycorine derivatives with anti-hand, foot and mouth virus activity (authorization announcement number CN 110759927B, application date: July 27, 2018).

[0004]

[0005] The present invention focuses on the oxidation of the 2-hydroxyl group of lycorine to a carbonyl group and conducts in-depth structural optimization exploration to obtain a class of lycorine derivatives, which show good anti-new coronavirus activity.

[0006] References:

[0007] Zeng Binglin, et al. Research progress on pharmacological activity and structure-activity relationship of lycorine[J]. Natural Product Research and Development, 2021, 33(02): 342-351. Summary of the invention

[0008] The technical problem solved by the present invention is to provide a class of lycorine derivatives and pharmaceutically acceptable salts thereof, and use of the pharmaceutical composition thereof in preparing antiviral drugs.

[0009] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions:

[0010] The first aspect of the technical solution of the present invention is to provide a class of lycorine derivatives and pharmaceutically acceptable salts thereof having the following general formula (I):

[0011]

[0012] in:

[0013] R is hydrogen, C3-6 cycloalkylcarbonyl, difluoro-substituted cyclobutanecarbonyl, phenoxyacetyl or halogen-substituted phenoxyacetyl, phenylthioacetyl or halogen-substituted phenylthioacetyl, 2-(halogen-substituted phenoxy)propionyl, 2-(halogen-substituted phenoxy)isobutyryl, N-phthalimidoacetyl.

[0014] The substituents of the halogen-substituted phenoxy group and the halogen-substituted phenylmercapto group are substituted at the para-position, meta-position, or ortho-position on the phenyl group, and the number of the substituents is single substitution, double substitution, or multiple substitution.

[0015] The halogen is F, Cl, Br, or I.

[0016] The most preferred lycorine derivatives and pharmaceutically acceptable salts thereof are selected from the following compounds:

[0017]

[0018] The second aspect of the technical solution of the present invention is to provide a pharmaceutical composition, which comprises a lycorine derivative according to any one of claims 1 to 4 and a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. The compounds of the present invention can be administered orally in the form of capsules, tablets, powders, granules, syrups or similar dosage forms, or parenterally by injection, ointment, suppository or similar dosage forms. These pharmaceutical preparations can be prepared by ordinary methods using adjuvants well known in the art, such as adhesives, excipients, stabilizers, disintegrants, flavoring agents, lubricants, etc. Although the dosage varies with the symptoms and age of the patient, the nature and severity of the disease or disorder and the route and mode of administration, for adult patients, the normal administration of the compounds of the present invention is a total daily dose of 1 to 200 mg, preferably 5 to 50 mg, as a single dose, or in divided doses; for example, twice or three times a day; for intravenous injection, 0.1 to 100 mg, preferably 5 to 50 mg, can be administered once or three times a day.

[0019] The third aspect of the technical solution of the present invention provides the use of the lycorine derivatives and pharmaceutically acceptable salts thereof described in the first aspect or the pharmaceutical composition described in the second aspect in the preparation of antiviral drugs, wherein the virus is selected from the new coronavirus SARS-CoV-2.

[0020] Beneficial technical effects

[0021] The present invention focuses on providing lycorine derivatives shown in the general formula (I), which are mainly obtained by oxidizing the 2-hydroxyl group of lycorine to a carbonyl group and introducing different acyl groups into the 1-hydroxyl group. Through anti-new coronavirus activity screening, such derivatives have significant anti-new coronavirus activity, indicating that such derivatives have good antiviral prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Initial screening inhibition of all 2-carbonyllycorine derivatives on the SARS-CoV-2 GD108 strain (10 μmol / L)

[0023] Figure 2 EC of three effective 2-carbonyllycorine derivatives (LY155, LY208 and LY211) against the wild-type SARS-CoV-2 strain GD108 50 Measurement results

[0024] Figure 3 The median toxic concentration (CC) of three 2-carbonyllycorine derivatives (LY155, LY208 and LY211) 50 )Measurement results DETAILED DESCRIPTION

[0025] English name and abbreviation:

[0026] aq.: aqueous solution

[0027] CC 50 : Half toxic concentration

[0028] DCM: dichloromethane

[0029] DMEM: Dulbecco's modified Eagle's medium

[0030] DMF: N,N-dimethylformamide

[0031] DMSO: dimethyl sulfoxide

[0032] DMAP: 4-dimethylaminopyridine

[0033] EA: Ethyl acetate

[0034] EC 50 : 50% inhibition concentration

[0035] EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

[0036] EtOH: ethanol

[0037] FBS: Fetal bovine serum

[0038] LY: Lycorine

[0039] MOI: Multiplicity of Infection

[0040] OD: absorbance

[0041] PE: Petroleum ether (60-90℃)

[0042] Py: pyridine

[0043] SI: Selection Index (CC 50 / EC 50 )

[0044] rt: room temperature

[0045] μM: μmol / L

[0046] The present invention discloses a class of lycorine derivatives, including their salts, solvates, prodrugs and pharmaceutical compositions. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve the same. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0047] The present invention will be further described below in conjunction with embodiments:

[0048] General synthesis method of compounds:

[0049] The reaction formula is as follows:

[0050]

[0051] Reagents and conditions: (a) Dess-Martin reagent, DMF-Py, rt; (b) EDCI, DMAP, carboxylic acid, DMF.

[0052] General synthetic method:

[0053] Add 1.15g (4mmol) of lycorine to a 200mL single-mouth bottle, then add 75mL of DMF and 50mL of pyridine, stir at room temperature for a while to clarify, add Dess-Martin reagent, stir at room temperature until the raw material disappears under TLC monitoring. The reaction solution is evaporated to remove most of the solvent, ethyl acetate and water are added for extraction, then washed with saturated NaCl, dried over anhydrous sodium sulfate, filtered and dried to obtain a brown solid 2-carbonyllycorine (yield 45%), which is directly used for the next step of reaction synthesis.

[0054] Dissolve the corresponding organic acid (1.2mmol), EDCI (383mg, 2mmol), and DMAP (24mg, 0.2mmol) in 5mL of anhydrous DMF and stir at room temperature for 10min. Add 2-carbonyllycorine (about 1mmol) and stir at room temperature until TLC shows that the raw material reacts completely. Remove most of the solvent by rotary evaporation, add ethyl acetate and saturated NaHCO3 for extraction, separate the organic phase, wash with water, dry with anhydrous Na2SO4, filter and concentrate, and separate the crude product by column chromatography (petroleum ether-ethyl acetate = 1:1) to obtain the target compound.

[0055] Example 12-Carbonyl Lycorine (LY-11)

[0056]

[0057] Brown solid, yield 45%. 1 H NMR(400MHz,DMSO-d6)δ6.84(s,1H,H-11),6.71(s,1H,H-8),5.97-5.96(m ,2H,H-12),5.82-5.80(m,1H,H-3),4.41(d,J=2.8Hz,1H),4.07(d,J=14.2 Hz,1H,H-7),3.41(d,J=14.2Hz,1H,H-7),3.31(t,J=8.6Hz,1H),3.09(d,J =10.1Hz,1H),2.90-2.67(m,3H),2.38(q,J=8.3Hz,1H); ESI-MS:286[M+H] + .

[0058] Example 21-Cyclohexanecarbonyl-2-carbonyllycorine (LY-155)

[0059]

[0060] White solid, yield 45%. 1 H NMR (400MHz, CDCl3) δ6.70(s,1H),6.56(s,1H),5.98(s,2H),5.90(s,2H),4.17(d,J=14.1Hz,1H),3.60(d,J=14.1Hz,1H),3.54-3.39(m,1H),3 .27(d,J=10.2Hz,1H),3.17(d,J=9.9Hz,1H),2.86(s,2H),2.53(q,J=8. 8,8.3Hz,1H),2.23-2.11(m,1H),1.78-1.43(m,7H),1.38-1.20(m,3H). 13C NMR (101MHz, CDCl3) δ193.25,174.50,168.93,146.72,128.89,125.42,120.60,107.38,105.82,101.20 ,68.58,62.61,56.44,53.37,45.66,42.85,30.12,28.85,28.69,25.74,25.24,25.18.ESI-MS:396[M+H] + .

[0061] Example 31-Cyclopentyl-2-carbonyl Lycorine (LY-185)

[0062]

[0063] White solid, yield 40%. 1 H NMR (400MHz, CDCl3) δ6.70(s,1H),6.56(s,1H),5.98(s,2H),5.90(s,2H),4.16(d,J=14.1Hz,1H),3.59(d,J=14.1Hz,1H),3.45(dt,J= 9.1,4.5Hz,1H),3.26(d,J=10.0Hz,1H),3.16(d,J=9.7Hz,1H),2.86(s,2H),2.65-2.47(m,2H),1.74-1.64(m,2H),1.65-1.40(m,6H). 13 C NMR (101MHz, CDCl3) δ193.27,175.26,169.44,146.70,128.93,125.44,120.57,107.37,105.72,101 .18,68.73,62.62,56.46,53.37,45.69,43.62,30.12,30.02,29.58,25.65,25.59.ESI-MS:382[M+H] + .

[0064] Example 41-Cyclobutanecarbonyl-2-carbonyllycorine (LY-187)

[0065]

[0066] White solid, yield 41%. 1H NMR (400MHz, CDCl3) δ6.72(s,1H),6.56(s,1H),5.98(s,2H),5.90(s,2H),4.1 6(d,J=14.1Hz,1H),3.58(d,J=14.1Hz,1H),3.45(dt,J=9.1,4.5Hz,1H),3.26( d,J=11.7Hz,1H),3.14(d,J=9.9Hz,1H),2.98(p,J=8.3Hz,1H),2.86(s,2H),2 .52(q,J=8.7Hz,1H),2.16-2.05(m,2H),2.03-1.93(m,2H),1.89-1.75(m,2H). 13 CNMR (101MHz, CDCl3) δ193.16,174.04,168.98,146.60,128.84,125.29,120.44,107.27,105. 56,101.08,68.65,62.42,56.33,53.24,45.56,37.79,30.00,25.04,18.41.ESI-MS:368[M+H] +

[0067] Example 51-Cyclopropanecarbonyl-2-carbonyllycorine (LY-186)

[0068]

[0069] White solid, yield 43%. 1 H NMR (400MHz, CDCl3) δ6.60(s,1H),6.47(s,1H),5.89(d,J=2.7Hz,2H),5.81(d,J=8.2Hz,2H),4.07(d,J=14.1Hz,1H),3.52(d,J=14.1Hz,1H),3.35(d t,J=9.2,4.6Hz,1H),3.16(d,J=9.9Hz,1H),3.09(d,J=10.4Hz,1H),2.76( t,J=6.3Hz,2H),2.49-2.40(m,1H),1.39-1.27(m,1H),0.87-0.60(m,6H). 13C NMR (101MHz, CDCl3) δ193.09,173.66,168.95,146.79,128.84,125.41,120.59,107.41,105. 60,101.21,68.96,62.45,56.38,53.35,45.62,30.09,29.81,12.93,9.10.ESI-MS:354[M+H] +

[0070] Example 61-(3,3-difluorocyclobutane)formyl-2-carbonyllycorine (LY-206)

[0071]

[0072] Pale yellow solid, yield 33%. 1 H NMR (400MHz, CDCl3) δ6.67(s,1H),6.57(s,1H),6.00(s,2H),5.91(d,J=3.7Hz,2H),4.17(d,J=14.1Hz,1H),3.59 (d,J=14.1Hz,1H),3.47(dt,J=9.1,4.5Hz,1H),3.30(d,J=9.7Hz,1H),3.13(d,J=10.0Hz,1H),2.95-2.40(m,8H). 13 CNMR(101MHz, CDCl3)δ192.58,172.08,169.41,146.90,146.80,129.10,124.98,120.49,119.99(dd,J=269,267Hz),107.54, 105.34,101.30,69.66,62.47,56.39,53.33,45.56,38.63(t,J=24.6Hz),30.17,26.43(dd,J=13.9,6.3Hz).ESI-MS:404[M+H] +

[0073] Example 71-(N-phthalimido)acetyl-2-carbonyllycorine (LY-20)

[0074]

[0075] Off-white solid, yield 52%. 1H NMR (400MHz, CDCl3) δ7.79-7.69(m,4H,Ar-H),6.57(s,1H,H-11),6.40(s,1H,H-8),5.98-5.88(m,4H,H-1,3,12),4.2 8(s,1H,N-CH2),4.04(d,J=14.0Hz,1H,H-7),3.40(s,1H),3.30-3.24(m,2H),2.99(s,1H),2.82(s,2H),2.39(s,1H). 13 CNMR (126MHz, CDCl3) δ191.74,167.07,166.15,147.20,147.08,134.35,132.05,128.56,124.65,123 .74,120.73,107.49,105.33,101.46,70.77,62.47,56.31,53.47,45.45,39.06,30.14.HRMS(ESI)m / z C 26 H 21 N2O7[M+H] + Calculated value: 473.1343, measured value: 473.1327.

[0076] Example 8 Phenoxyacetyl-2-carbonyllycorine (LY-18)

[0077]

[0078] Yellow solid, yield 86%. 1 H NMR (500MHz, CDCl3) δ7.35-7.32(m,2H,Ar-H),7.07-6.99(m,4H,Ar-H),6.57(s,1 H,H-8),6.06(s,1H,H-3),5.95(s,1H,H-12),5.93(s,1H,H-12),5.57(d,J=13.0Hz ,1H,H-1),4.93(s,1H,O-CH2),4.14(d,J=14.6Hz,1H,H-7),3.62(d,J=14.6Hz,1H ,H-7),3.48-3.43(m,2H),3.06(d,J=10.5Hz,1H),2.85(s,2H),2.57-2.52(m,1H). 13C NMR (126MHz, CDCl3) δ192.14,168.43,168.26,157.79,146.79,146.69,129.63,128.73,127.15,121.77,1 20.46,114.69,107.15,107.10,101.20,78.05,66.59,65.41,56.76,53.67,44.48,29.89.HRMS(ESI)m / zr C 24 H 22 NO6[M+H] + Calculated value: 420.1442, measured value: 420.1429. Example 9 4-Fluorophenoxyacetyl-2-carbonyllycorine (LY-188)

[0079]

[0080] Pale yellow solid, yield 31%. 1 H NMR (400MHz, CDCl3) δ6.79(t,J=8.5Hz,2H),6.69(s,1H),6.55(d,J=7.4Hz,3H),6.09-5.88(m,4H),4.51(s,2H ),4.11(d,J=14.0Hz,1H),3.51-3.32(m,2H),3.26(d,J=9.6Hz,1H),2.99-2.70(m,3H),2.43(q,J=8.8Hz,1H). 13 C NMR(101MHz, CDCl3)δ192.05,169.47,167.89,157.65(d,J=239.2Hz),153.74,153.72,146.96,146.82,129.06,124.76,120.45,115.90 (d,J=23.2Hz),115.44(d,J=8.1Hz),107.59,105.45,101.34,69.96,65.53,62.26,56.30,53.30,45.56,30.10,29.83.ESI-MS:438[M+H] +

[0081] Example 10 Benzenethioacetyl-2-carbonyllycorine (LY-16)

[0082]

[0083] Yellow oil, yield 46%. 1H NMR(400MHz, CDCl3)δ7.17-7.10(m,5H,Ar-H),6.69(s,1H,H-11),6.52(s,1H,H-8),5 .97-5.94(m,2H,H-1,H-3),5.89(d,J=1.5Hz,1H,H-12),5.87(d,J=1.5Hz,1H,H-12), 4.11(d,J=14.1Hz,1H,H-7),3.51-3.47(m,3H,H-7,S-CH2),3.45-3.40(m,1H),3.25- 3.22(m,1H),2.98(dd,J=10.0,2.1Hz,1H),2.84-2.80(m,2H),2.59(q,J=8.4Hz,1H). 13 C NMR (126MHz, CDCl3) δ192.19,169.31,168.31,163.36,160.90,146.75,146.63,132.88,32.80,129.46,129.43,128,84,1 24.82,120.33,116.15,115.93,107,34,105.41,101.15,70.06,62.16,56.24,53.18,45.50,37.12,29.98.HRMS(ESI)m / z C 24 H 22 NO5S[M+H] + Calculated value: 436.1213, measured value: 436.1215.

[0084] Example 114-Fluorophenylthioacetyl-2-carbonyllycorine (LY-11)

[0085]

[0086] Pale yellow solid, yield 41%. 1 H NMR (400MHz, CDCl3) δ7.15(t,J=8.5Hz,2H),6.88(t,1H),6.67(s,J=7.4Hz,3H),6.54(s,4H),5.96(d,2H),5.90(t,J =14.0Hz,2H),4.15(d,2H),3.53(d,1H),3.45(s,2H),3.42(d,1H),2.85(d,1H),2.83(m,2H),1.26(q,J=8.8Hz,1H). 13CNMR(101MHz, CDCl3)δ192.05,169.47,167.89,157.65(d,J=239.2Hz),153.74,153.72,146.96,146.82,129.06,124.76,120.45,115.9 0(d,J=23.2Hz),115.44(d,J=8.1Hz),107.59,105.45,101.34,69.96,65.53,62.26,56.30,53.30,45.56,30.10,29.83.HRMS(ESI)m / zC 24 H 21 NFO5S[M+H] + Calculated value: 454.1119, measured value: 454.1113.

[0087] Example 124-Chlorophenoxypropionyl-2-carbonyllycorine (LY-209)

[0088]

[0089] White solid, yield 31%. 1 H NMR (400MHz, CDCl3) δ7.25 (d, J = 6.0Hz, 1H), 7.07 (s, 1H), 6.94-6.79 (m, 2H), 6.74-6.63 (m, 1H), 6.55 (s, 1H), 6.01-5.80 (m, 4H), 4.13(d,J=14.0Hz,1H),3.68-3.32(m,3H),3.32-3.16(m,1H),3.05-2.71(m,3H),2.48(d,J=11.4Hz,1H),1.28(d,J=7.7Hz,3H). 13 C NMR (101MHz, CDCl3) δ192.50, 171.35, 162.71 (d, J = 248.2Hz), 146.83, 146.75, 136.13 (d, J = 8.3Hz), 135.44 (d, J = 8.4Hz), 128.83, 125.01, 120.49,115.95(d,J=21.8Hz),107.45,105.76,105.39,101.22,69.88,62.29,56.25,53.25,44.82,30.05,17.03,16.84.ESI-MS:468[M+H] +

[0090] Example 134-Fluorophenylmercaptopropionyl-2-carbonyllycorine (LY-177)

[0091]

[0092] White solid, yield 31%. 1 H NMR (400MHz, CDCl3) δ7.25 (d, J = 6.0Hz, 1H), 7.07 (s, 1H), 6.94-6.79 (m, 2H), 6.74-6.63 (m, 1H), 6.55 (s, 1H), 6.01-5.80 (m, 4H), 4.13(d,J=14.0Hz,1H),3.68-3.32(m,3H),3.32-3.16(m,1H),3.05-2.71(m,3H),2.48(d,J=11.4Hz,1H),1.28(d,J=7.7Hz,3H). 13 C NMR (101MHz, CDCl3) δ192.50, 171.35, 162.71 (d, J = 248.2Hz), 146.83, 146.75, 136.13 (d, J = 8.3Hz), 135.44 (d, J = 8.4Hz), 128.83, 125.01, 120.49,115.95(d,J=21.8Hz),107.45,105.76,105.39,101.22,69.88,62.29,56.25,53.25,44.82,30.05,17.03,16.84.ESI-MS:468[M+H] +

[0093] Example 144-Fluorophenoxybutyryl-2-carbonyllycorine (LY-153)

[0094]

[0095] White solid, yield 33%. 1 H NMR (400MHz, CDCl3) δ6.92(d,J=8.4Hz,2H),6.78(s,1H),6.57(s,1H),6.45(d,J=8.4Hz,2H),5.99(s,2H),5.94(s,2H),4.07(d ,J=13.9Hz,1H),3.44-3.30(m,2H),3.26(d,J=9.7Hz,1H),2.92-2.75(m,3H),2.39(q,J=8.5Hz,1H),1.43(s,3H),1.41(s,3H). 13C NMR (101MHz, CDCl3) δ192.19,172.76,169.55,153.86,146.88,146.73,129.00,126.63,124.91,120.35,119. 54,107.67,105.63,101.83,79.26,70.35,62.38,56.27,53.22,45.12,30.08,26.22,24.62.ESI-MS:482[M+H] +

[0096] Pharmacological experiments

[0097] Experimental Example 1 Preliminary screening results of in vitro anti-new coronavirus activity of lycorine derivatives (10 μmol / L, Figure 1 )

[0098] (1) Compound preparation and challenge experiments

[0099] The density is 2×10 5 / mL Vero cells were plated on 96-well plates, 100 μL per well, and cultured overnight. Weigh appropriate amounts of lycorine and lycorine derivatives and prepare them into 10mM storage solution with DMSO. When used, the drug was prepared to 10μM with DMEM or DMEM containing 2% FBS. After the drug to be tested was diluted with DMEM (concentration of 10μM) to treat Vero cells for 1 hour (96-well plate, 100μL / well), the virus (100μL / well) was added to infect Vero cells for 1 hour (MOI=0.05), the drug-virus mixture was discarded, and the drug diluted with 2% FBS DMEM (concentration of 10μM) was added again, and incubated in a 37°C incubator for 48 hours. Observe the cytopathic effect (CPE) after the drug action, take 100μL of the cultured cell supernatant, add 200μL triazole treatment, and extract RNA with a nucleic acid extraction kit for subsequent experiments.

[0100] (2) Real-time fluorescence quantitative detection of viral RNA copy number

[0101] The SARS-CoV-2 N protein (Nucleocapsidprotein) gene primers and carboxyfluorescein (FAM) fluorescent probe (synthesized by Sangon Biotechnology) were diluted to 5 μM, and the N plasmid was used as a standard (constructed by Peng Xiaozhong's laboratory). Tenfold gradient dilutions were performed starting from 10 ng / μL, and a total of 8 concentration gradients were used to calculate the standard curve. The copy number of the viral N gene was calculated based on the standard curve (absolute quantification). The following components were added to the 384-well white bottom plate and centrifuged:

[0102]

[0103] Get a total reaction volume of 10 μL and set up the PCR machine to run as follows:

[0104]

[0105] After the instrument is finished running, the N gene copy number of the sample will be calculated based on the standard curve, and the compound's inhibition rate on the virus will be calculated by the formula = (N gene copy number of the virus control group - N gene copy number of the drug group) / N gene copy number of the virus control group × 100% to calculate the compound's inhibition rate on viral replication.

[0106] from Figure 1 The preliminary screening results against the new coronavirus GD108 strain showed that lycorine, LY155, LY208, LY211 and LY14 all had significant inhibitory effects on the new coronavirus GD108 strain, showing a certain inhibition rate at a dosage concentration of 10 μM, while the inhibition rate of compound LY155 at 10 μM was similar to that of lycorine, suggesting that the three effective compounds LY155, LY208 and LY211 can be further determined by their EC 50 value.

[0107] Experimental Example 2 In vitro effective compound EC 50 Determination of

[0108] (1) Compound preparation and challenge experiments

[0109] The density is 2×10 5 / mL Vero cells were plated on 96-well plates, 100 μL per well, and cultured overnight. Appropriate amounts of lycorine and lycorine derivatives were weighed and prepared into 10mM storage solution with DMSO. The drug was diluted 2-fold with DMEM or DMEM containing 2% FBS (starting from 10 μM), with a total of 7 concentration gradients. After treating Vero cells with the drug to be tested diluted with DMEM for 1 hour (96-well plate, 100 μL / well), the virus (100 μL / well) was added to infect Vero cells for 1 hour (MOI = 0.05), the drug-virus mixture was discarded, and the drug diluted with 2% FBS DMEM was added again, and incubated in a 37°C incubator for 48 hours. Observe the cytopathic effect (CPE) after the drug action, take 100 μL of the cultured cell supernatant, add 200 μL of triazole treatment, and extract RNA with a nucleic acid extraction kit for subsequent experiments.

[0110] (2) Real-time fluorescence quantitative detection of viral RNA copy number

[0111] The detection method was the same as that in Experimental Example 1. After calculating the inhibition rate of virus replication at different gradient concentrations of the compound, the statistical software GraphPad Prism 8 was used to plot and calculate the half-maximal inhibitory concentration (EC) of the drug on viral N gene replication. 50, 50% inhibitory concentration).

[0112] Further testing of LY155, LY208 and LY211 on the wild-type SARS-CoV-2 strain GD108 revealed that derivatives LY155 and LY208 had relatively small EC 50 value( Figure 2 ), compound LY211 has a larger EC 50 value.

[0113] Experimental Example 3 EC 50 CC of the most effective compounds 50 Determination (CCK8 method)

[0114] Compound CC 50 The determination method is as follows:

[0115] The density is 2×10 5 / mL Vero cells were added to a 96-well plate, 100 μL per well, and cultured overnight. Gradient dilutions were made to 50, 25, 12.5, 6.25, 3.13, 1.56, and 0.78 μM using DMEM (Dulbecco's modified Eagle's medium) or DMEM medium containing 2% FBS. The medium in the 96-well plate was discarded, and 200 μL of the compound diluted in DMEM was added to each well, and the cells were incubated in a 37°C incubator for 48 hours. The medium was discarded, and 100 μL of DMEM medium containing CCK-8 was added, and the cells were incubated at 37°C for 2 hours. Negative control wells (adding 0.1% DMSO) and blank control wells (no cells, adding DMEM) were set up. The absorbance value was measured at a wavelength of 450 nm using an ELISA reader, and the cell inhibition rate of the compound was calculated using the formula: inhibition rate = (negative control group - drug group) / (negative control group - blank group) × 100%, where negative was the average absorbance (OD) of the negative control group, the drug group was the average OD of the compound group, and blank was the average OD of the blank group. The CC was calculated using the statistical software GraphPad prism 8. 50 .

[0116] from Figure 3 It can be seen that the experimentally measured half toxic concentration (CC 50 ) were 164.6, 281.8 and 158.8 μM, respectively, indicating that its toxicity was superior to that of lycorine (CC 50 53.31μM).

[0117] By calculating the selectivity index (SI) of the three compounds, the SI values ​​of these three compounds were 96.88, 92.48 and 12.46, respectively, while the SI value of lycorine was 80.17. The research results showed that compounds LY155 and LY208 have significant anti-new coronavirus effects and are worthy of further development.

Claims

1. A lycorine derivative or a pharmaceutically acceptable salt thereof having the following general formula (I): in: R is hydrogen, C3-6 cycloalkylcarbonyl, difluoro-substituted cyclobutanecarbonyl, phenoxyacetyl or halogen-substituted phenoxyacetyl, phenylthioacetyl or halogen-substituted phenylthioacetyl, 2-(halogen-substituted phenoxy)propionyl, 2-(halogen-substituted phenoxy)isobutyryl, N-phthalimidoacetyl.

2. The lycorine derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The substituents of the substituted phenoxy group and the substituted phenylthio group are substituted at the para position, meta position or ortho position on the phenyl group, and the number of the substituents is mono-substituted, di-substituted or poly-substituted.

3. The lycorine derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The halogen is F, Cl, Br, or I.

4. The lycorine derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The compound is selected from the following:

5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the lycorine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutical composition includes tablets, capsules, pills, injections, eye drops, sprays and ointments.

7. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutical composition is selected from controlled-release dosage forms, sustained-release dosage forms, and various microparticle delivery systems.

8. Use of the lycorine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 in the preparation of antiviral drugs.

9. The use according to claim 8, characterized in that The virus is selected from the group consisting of the new coronavirus SARS-CoV-2, coronavirus SARS-CoV, hand, foot and mouth virus EV71, Coxsackievirus A16, and Zika virus.

Citation Information

Patent Citations

  • Lycorine derivative, veterinary drug taking lycorine derivative as an active constituent, and applications of lycorine derivative

    CN103012420A

  • Application of Lycorine compound in preparation of anti-tumor drugs

    CN103304573A

  • Medicine for preventing and treating Zika virus infection and application of lycorine in preparation of medicine for preventing and treating Zika virus infection

    CN110755436A

  • Lycorinine derivative as well as pharmaceutical composition and application thereof

    CN110759927A

  • Application of lycorine hydrochloride thioester in preparation of anti-coronavirus medicine

    CN113967211A